Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study.

Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, McCracken JT, Fava M, Iosifescu D, Greenwald S.

Psychiatry Res. 2009 Sep 30;169(2):124-31. doi: 10.1016/j.psychres.2009.06.004.

PMID:
19712979
2.

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.

Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S.

Psychiatry Res. 2009 Sep 30;169(2):132-8. doi: 10.1016/j.psychres.2009.04.004.

PMID:
19709754
3.

Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.

Cook IA, Hunter AM, Gilmer WS, Iosifescu DV, Zisook S, Burgoyne KS, Howland RH, Trivedi MH, Jain R, Greenwald S, Leuchter AF.

J Clin Psychiatry. 2013 Jan;74(1):51-6. doi: 10.4088/JCP.10m06813.

PMID:
23419226
4.

[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].

Azorin JM, Llorca PM, Despiegel N, Verpillat P.

Encephale. 2004 Mar-Apr;30(2):158-66. French.

PMID:
15107719
5.

The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder.

Caudill MM, Hunter AM, Cook IA, Leuchter AF.

Clin EEG Neurosci. 2015 Oct;46(4):277-84. doi: 10.1177/1550059414532443.

PMID:
25258429
6.

Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder.

Iosifescu DV, Greenwald S, Devlin P, Perlis RH, Denninger JW, Alpert JE, Fava M.

Acta Psychiatr Scand. 2008 Apr;117(4):271-6. doi: 10.1111/j.1600-0447.2008.01156.x.

PMID:
18307587
7.

The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine.

Hunter AM, Cook IA, Greenwald SD, Tran ML, Miyamoto KN, Leuchter AF.

J Clin Neurophysiol. 2011 Oct;28(5):478-82. doi: 10.1097/WNP.0b013e318230da8a.

8.

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.

Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, Modell JG.

J Clin Psychiatry. 2006 May;67(5):736-46.

PMID:
16841623
9.

Frontal EEG predictors of treatment outcome in major depressive disorder.

Iosifescu DV, Greenwald S, Devlin P, Mischoulon D, Denninger JW, Alpert JE, Fava M.

Eur Neuropsychopharmacol. 2009 Nov;19(11):772-7. doi: 10.1016/j.euroneuro.2009.06.001.

PMID:
19574030
10.

Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant?

Gerra ML, Marchesi C, Amat JA, Blier P, Hellerstein DJ, Stewart JW.

J Clin Psychiatry. 2014 Sep;75(9):e939-44. doi: 10.4088/JCP.14m09025.

PMID:
25295437
11.

An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.

Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M.

J Clin Psychiatry. 2005 Aug;66(8):1038-42.

PMID:
16086620
12.

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

Mao PX, Tang YL, Jiang F, Shu L, Gu X, Li M, Qian M, Ma C, Mitchell PB, Cai ZJ.

Depress Anxiety. 2008;25(1):46-54.

PMID:
17149753
14.

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team..

Am J Psychiatry. 2006 Jan;163(1):28-40.

PMID:
16390886
15.

Early symptom change prediction of remission in depression treatment.

Katz MM, Meyers AL, Prakash A, Gaynor PJ, Houston JP.

Psychopharmacol Bull. 2009;42(1):94-107.

PMID:
19204654
16.

Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.

Mrazek DA, Biernacka JM, McAlpine DE, Benitez J, Karpyak VM, Williams MD, Hall-Flavin DK, Netzel PJ, Passov V, Rohland BM, Shinozaki G, Hoberg AA, Snyder KA, Drews MS, Skime MK, Sagen JA, Schaid DJ, Weinshilboum R, Katzelnick DJ.

J Clin Psychopharmacol. 2014 Jun;34(3):313-7. doi: 10.1097/JCP.0000000000000099. Erratum in: J Clin Psychopharmacol. 2014 Oct;34(5):558.

17.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
18.
19.

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP.

CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.

PMID:
21323394
20.

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

Burke WJ, Gergel I, Bose A.

J Clin Psychiatry. 2002 Apr;63(4):331-6.

PMID:
12000207
Items per page

Supplemental Content

Support Center